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Neuronal Nitric Oxide Synthase and
Human Vascular Regulation
Narbeh Melikian, Michael D. Seddon, Barbara Casadei,
Philip J. Chowienczyk, and Ajay M. Shah⁎
Vascular blood flow and its distribution among different vascular beds
are regulated by changes inmicrovascular tone. Nitric oxide (NO) plays a
key role in the local paracrine regulation of vessel tone both under resting
conditions and when blood flow increases in response to agonist
stimulation or increased shear stress. The conventional notion that
endothelial NO synthase (eNOS)-derived NO is largely responsible for
both effects has been challenged by first-in-human studies with a
selective inhibitor of neuronal NOS (nNOS), S-methyl-L-thiocitrulline
(SMTC). These studies reveal that SMTC causes a reduction in basal
blood flow in the normal human forearm and coronary circulations (that
is reversed by L-arginine), without affecting the eNOS-mediated
vasodilatation elicited by acetylcholine, substance P, or increased shear
stress. S-methyl-L-thiocitrulline also inhibits mental stress-induced
vasodilatation. These results are consistent with a significant body of
experimental studies suggesting that nNOS plays an important role in the
local regulation of vessel tone in other species, independent of the effects
of nNOS-derived NO in the central nervous system. These emerging data
suggest that eNOS and nNOS have distinct roles in the physiologic local
regulation of human microvascular tone in vivo and pave the way for
further detailed investigation of the relative contribution of nNOS and
eNOS in vascular regulation in human disease. (Trends CardiovascMed
2009;19:256–262) n 2009, Elsevier Inc.
 Introduction
The regulation of blood flow distribution
among different vascular beds according
to varying metabolic requirements is
fundamentally important in ensuring a
match between tissue perfusion and
metabolism. This is primarily achieved
through complex adjustments in the tone
and thus resistance of the microcircula-
tion. Dysregulation or impairment of
microvascular function may lead to
organ dysfunction in virtually any body
system. At a local level, nitric oxide (NO)
is well known to play a pivotal role in the
NarbehMelikian, Michael D. Seddon, Philip J.
Chowienczyk, and Ajay M. Shah are at the
Kung's College London British Heart Founda-
tion Centre of Excellence, Cardiovascular
Division, London, United Kingdom. Barbara
Casadei is at the Department of Cardiovascu-
lar Medicine, University of Oxford, Oxford,
United Kingdom.
⁎ Address correspondence to: Dr. Ajay M.
Shah, Cardiovascular Division, The James
Black Centre, King's College London School
of Medicine, 125 Coldharbour Lane, SE5 9NU
London, United Kingdom. Tel.: (+44) 20-7848-
5189; fax: (+44) 20-7848-5193; e-mail: ajay.
shah@kcl.ac.uk.
© 2009, Elsevier Inc.
1050-1738
TCM Vol. 19, No. 8, 2009256
Open access under CC BY license.
Open access under CC BY license.
modulation of microvascular tone (Mon-
cada and Higgs 1993, 2006). Nitric oxide
(NO) has potent vasodilator effects that
interact with other local vasoactive med-
iators (eg, prostanoids, endothelin, and
the endothelium-derived hyperpolariz-
ing factor) and with neural inputs to
determine overall vascular tone and
blood flow (Moncada and Higgs 1993,
2006). Although three distinct isoforms
of NO synthase (NOS)—endothelial NOS
(eNOS), neuronal NOS (nNOS), and
inducible NOS—may generate NO with
the use of L-arginine as substrate, it has
generally been accepted that the local
regulation of vascular tone in health is
primarily dependent upon the release of
NO from eNOS (Deanfield et al. 2007,
Moncada and Higgs 2006). However, an
emerging literature from animal studies
has suggested that nNOS-derived NO
may also be involved in this process.
These experimental findings have now
been complemented by a series of recent
first-in-human studies providing evi-
dence that nNOS-derived NO plays an
important role in the local regulation of
basal microvascular tone as well as in the
vasodilator response to mental stress.
 Endothelial NOS and
acute vasodilatation
A large body of data from animal and
human studies for more than two dec-
ades indicates that NO generated in the
endothelium induces paracrine relaxa-
tion of vascular smooth muscle cells
leading to a reduction in vascular tone
(Moncada et al. 1993, 2006, Palmer et al.
1988). These NO-dependent vasodilator
effects are elicited by increases in endo-
thelial pulsatile shear stress or by a wide
variety of agonists (eg, acetylcholine,
substance P, and thrombin) that act on
the vascular endothelium (Deanfield et
al. 2007, Vallance and Chan 2001). The
most compelling evidence that these
effects involve eNOS comes from studies
in eNOS knockout mice, where both
agonist- and flow-induced NO-depen-
dent vasorelaxation are impaired (God-
ecke et al. 1998, Huang et al. 1995,
Scotland et al. 2002). In humans, the
NO synthase inhibitor NG monomethyl-
L-arginine (L-NMMA) inhibits both ago-
nist- and flow-induced vasodilatation in
several vascular beds (including the
forearm and coronary circulation) pro-
viding further evidence that NO is in-
volved in the regulation of vascular tone
(Drexler 1997, Moncada et al. 1993,
2006). Although L-NMMA inhibits the
activity of all NOS isoforms, the obser-
vation that eNOS is the major NOS
isoform expressed in endothelial cells
combined with ex vivo studies in
human vessels confirming the central
role of the endothelium in vascular
responses support the conclusion that
eNOS is the predominant source of NO
responsible for the regulation of vascular
tone (Moncada et al. 1993, 2006). This
conclusion is further supported by evi-
dence that impairment of eNOS-depen-
dent (agonist- and flow-induced)
vasodilatation in humans (generally
termed endothelial dysfunction) is a prog-
nostic marker for future atherosclerosis-
related cardiovascular events (Landmes-
ser et al. 2004, Quyyumi 2003).
 Nitric oxide-dependent regulation
of basal vascular tone
Experimental studies with the use of L-
NMMA and other nonselective NOS
inhibitors have suggested that continu-
ous release of NO from the endothelium
might tonically reduce basal microvas-
cular tone in vivo—an effect termed tonic
vasodilatation (Moncada et al. 1993,
2006). In healthy humans, seminal stud-
ies by Vallance et al. (Vallance et al. 1989)
found that local forearm infusion of L-
NMMA reduced resting blood flow. The
effects of L-NMMA were abrogated by L-
arginine but not D-arginine, indicating
that stereospecific inhibition of the L-
arginine/NO pathway was involved (Val-
lance et al. 1989). Similar results have
been confirmed by numerous investiga-
tors, and the data extended to other
vascular beds, including the coronary
and pulmonary circulations (Moncada
et al. 1993, 2006). Because L-NMMA
reduces basal NO production by cultured
endothelial cells and induces vasocon-
striction in isolated vascular rings, and
eNOS-derived NO is involved in agonist-
induced vasodilation, it has generally
been considered that sustained release
of NO by eNOS is the underlying mech-
anism for “tonic vasodilatation” observed
in vivo (Moncada et al. 1993, 2006).
Further data that are often interpreted
as supporting NO-dependent tonic vaso-
dilatation are the findings from both
animal and human studies that systemic
infusion of L-NMMA causes acute dose-
dependent hypertension (Rees et al.
1989, Haynes et al. 1995).
However, it is important to recognize
that the above data do not offer definitive
proof for the involvement of eNOS in
regulation of vascular tone. Although L-
NMMA is specific for NOS, it is nonse-
lective for its three isoforms and, there-
fore, does not provide any evidence for
the involvement of an individual NOS
isoform. With regard to the data on L-
NMMA-induced hypertension, it should
be noted that both kidney function and
autonomic nerve activity are influenced
by NO and have a major impact on blood
pressure regulation; thus, the systemic
effects of NOS inhibition cannot be
interpreted as merely reflecting changes
in endothelial function and local vascular
tone. In addition, there are incongruous
results from human studies that provide
a basis to challenge the notion that eNOS
is the major source of NO responsible for
the local regulation of microvascular
tone. For example, several investigators
have shown that there is often a poor
correlation between basal and stimulated
NO-dependent vasodilatation within the
same vascular bed—with a reduction in
the stimulated response but a relative
preservation of the basal response (Dean-
field et al. 2007, Drexler 1997). Such
differences are particularly marked in
the presence of cardiovascular risk fac-
tors or in individuals with established
atherosclerotic vascular disease. In fact,
direct in vivo evidence that a continuous
eNOS-dependent local release of NO
modulates basal vascular tone is lacking.
Hence, the question arises whether local
regulation of basal microvascular tone by
NO is subserved by a different source of
NO.
 Neuronal NOS and vascular tone
The nNOS isoform is expressed in most
regions of the central nervous system, in
parasympathetic ganglia and in selected
nonadrenergic noncholinergic peripheral
autonomic nerve fibers (or “nitrergic”
nerves) (Schuman and Madison 1994,
Toda and Okamura 2003). The nNOS-
derived NO is an important neurotrans-
mitter that is involved in neuronal plastic-
ity (in particular in memory formation),
regulationof central nervous systemblood
flow, peripheral and central transmission
of pain signals, neurotransmitter release
from cholinergic nerve fibers, and the
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functional regulation of organs with
nitrergic innervation (Schuman and
Madison 1994, Toda and Okamura
2003). In addition to the central nervous
system, nNOS is now known to also be
expressed in many nonneuronal cell types
such as skeletal (Kobzik et al. 1994) and
cardiac myocytes (Xu et al. 1999), cells of
the macula densa within the kidney
(Bachmann et al. 1995), and selected
smooth muscle (Boulanger et al. 1998)
and endothelial (Bachetti et al. 2004) cells.
The availability of selective nNOS inhibi-
tors, as well as studies in gene-modified
mice with perturbation of nNOS expres-
sion, have provided evidence that non-
neuronal nNOS is physiologically active
and exerts important regulatory influ-
ences in a number of different tissues.
A significant body of in vitro and in
vivo experimental data implicates nNOS-
derived NO in local physiologic regula-
tion of vascular tone acting through
several different mechanisms. These
local regulatory influences appear to be
independent of any central actions of
nNOS that affect autonomic function. In
the renal and cerebral circulation, a
number of studies have suggested that
nNOS-derived NO is involved in the
autoregulation of local blood flow
through direct effects on vascular
smooth muscle (Bauser-Heaton and
Bohlen 2007, Chi et al. 2003, Hudetz
et al. 1998, Ichihara et al. 1998, Mattson
and Meister 2005, Pelligrino et al. 1993,
Santizo et al. 2000, Sigmon and Beier-
waltes 2000, Vallon et al. 2001).
With the use of the selective nNOS-
inhibitor S-methyl-L-thiocitrulline
(SMTC) in explanted whole rat kidneys,
Ichihara et al. (Ichihara et al. 1998)
provided the first direct evidence for
nNOS-dependent regulation of vascular
tone in the kidney. Selective inhibition of
nNOS decreased basal afferent and ef-
ferent arteriolar tone but had no effect on
vasodilatation in response to the eNOS
agonist acetylcholine. These investiga-
tors further demonstrated that removal
of the cells of the macula densa by
papillectomy (the main source of renal
nNOS) abolished the vasoconstrictor
effects of SMTC (Ichihara et al. 1998).
Additional direct evidence for the role of
nNOS-derived NO in the kidney is de-
rived from nNOS knockout mice
(nNOS−/−), where the regulatory influ-
ences of the macula densa are signifi-
cantly attenuated (Vallon et al. 2001).
Other studies have suggested that
nNOS may be involved in the reflex
regulation of cerebral vascular tone and
blood flow, particularly in response to
hypoxia and/or hypotension (Bauser-
Heaton and Bohlen 2007, Chi et al.
2003, Hudetz et al. 1998, Pelligrino et
al. 1993, Santizo et al. 2000). For exam-
ple, with the use of an in vivo rat model,
Bauser-Heaton et al. (Bauser-Heaton and
Bohlen 2007) demonstrated that selec-
tive inhibition of nNOS with N-(4S)-(4-
amino-5-[aminoethyl]aminopentyl)-N'-
nitroguanidine reduced basal cerebral
arterial diameter and abolished the va-
sodilator response to hypoxia. In con-
trast, flow-mediated dilatation (a
predominant eNOS-mediated response)
remained intact in the presence of selec-
tive nNOS inhibition. This study did not
directly investigate the cellular sources of
nNOS, which could potentially include
the arteriolar smooth muscle cell or
perivascular nerve fibers.
Other studies provide evidence that
nNOS-derived NOmay alter vascular tone
through inhibition of perivascular sympa-
thetic nerve activity. In isolated rat mes-
enteric arteries without endothelium,
Hatanaka et al. (Hatanaka et al. 2006)
showed that selective nNOS inhibition
with vinyl-L-5-(1-imino-3-butenyl)-L-orni-
thine (L-VNIO) augmented arterial vaso-
constriction and local norepinephrine
concentration in response to perivascular
nerve stimulation. However, L-VNIO did
not influence the vasoconstrictor re-
sponse to exogenous norepinephrine,
suggesting that nNOS-derived NO may
affect neurotransmitter release from peri-
vascular sympathetic nerves. Consistent
with this idea, immunostaining of mesen-
teric artery specimens localized nNOS to
perivascular capsaicin-sensitive sensory
nerve fibers, whereas the functional de-
pletion of nNOS-immunopositive fibers
with capsaicin abolished the augmented
vasoconstrictor response to nerve stimu-
lation (Hatanaka et al. 2006). Taken
together, these observations suggest that
nNOS-derived NO released from capsai-
cin-sensitive sensory nerve fibers may
presynaptically modulate adrenergic sym-
pathetic neurotransmission and hence
vascular tone.
Skeletal muscle may be an additional
source of nNOS-derived NO with impor-
tant influences on vascular tone. In
normal skeletal muscle, nNOS is located
at the cell membrane bound to the
cytoskeletal protein dystrophin (Bren-
man et al. 1995, Chang et al. 1996). The
absence of dystrophin, as seen in patients
with Duchenne muscular dystrophy
(DMD) and its animal equivalent the
mdx mouse, leads to a significant reduc-
tion in skeletal muscle nNOS expression
and in skeletal muscle blood flow (Bren-
man et al. 1995). With the use of themdx
mouse model, Thomas et al. (Thomas et
al. 1998) showed that the normal ability
to attenuate α-adrenergic vasoconstric-
tion in response to sciatic nerve stimula-
tion in the hind limb was significantly
impaired in a similar manner to that
observed in nNOS-deficient mice. Fur-
thermore, nNOS-deficient mice did not
exhibit any enhancement of vasocon-
striction in the contracting hind limb
after treatment with N-nitro-L-arginine
methyl ester (L-NAME) (Thomas et al.
1998). Taken together, these findings
suggest that NO derived from nNOS
may have an important role in maintain-
ing blood flow in the exercising skeletal
muscle by reducing α-adrenergic vaso-
constriction and that its absence may
account for the abnormal vascular
responses seen in contracting limbs of
mdx mice or nNOS knockout mice.
 In vivo human evidence for
nNOS-mediated regulation of
vascular tone
The main tools available to study NOS-
dependent effects in humans in vivo have
until recently been the nonselective NOS
inhibitor L-NMMA and agonists such as
acetylcholine that induce eNOS activa-
tion. The lack of isoform-selective NOS
inhibitors suitable and validated for in
vivo human use has been a major
limitation to assessing the relative roles
of individual NOS isoforms in the regu-
lation of cardiovascular responses.
Limited circumstantial evidence for a
potential role of nNOS-derived NO in the
regulation of human vascular tone was
initially obtained from studies in chil-
dren with DMD, who are presumed to be
deficient in skeletal muscle nNOS activ-
ity (Sander et al. 2000). In studies
analogous to those described above for
the mdx mouse model, Sander et al
found that children with DMD had no
blunting of the vasoconstrictor response
(measured as a decrease in muscle
oxygenation) to reflex sympathetic acti-
vation during forearm exercise (Sander
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et al. 2000). In contrast, the same
stimulus led to reduced vasoconstriction
in healthy children or in patients with
different muscle disorders where nNOS
expression was expected to be intact
(Sander et al. 2000). Additional indirect
evidence for the vascular influences of
nNOS was derived from studies in renal
transplant patients. Kwon et al. (Kwon
et al. 2009) demonstrated that impaired
graft vascular function subsequent to
renal transplantation, a condition that
encompasses altered renal vascular tone
and loss of vascular autoregulation, was
associated with diminished staining for
nNOS in renal biopsy specimens.
The first direct evidence for an involve-
ment of nNOS-derived NO in the regula-
tion of basal vascular tone in healthy
humans has recently been provided by
Seddon et al. (Seddon et al. 2008) in first-
in-human studies with the nNOS-selective
inhibitor SMTC. The local infusion of
SMTC into the brachial artery of healthy
subjects led to a significant dose-depen-
dent reduction in basal forearm blood
flow as measured by venous occlusion
plethysmography. This response was
abolished in the presence of excess L-
arginine, but not D-arginine, indicating
that the effects of SMTC were mediated
through stereospecific inhibition of the L-
arginine/NO pathway (Figure 1). The
reduction in basal forearm blood flow
induced by SMTC occurred at a signifi-
cantly (N10-fold) lower concentration
than L-NMMA, consistent with the greater
potency of the former agent for nNOS
inhibition. Importantly, SMTC had no
effect on the increases in forearm blood
flow elicited by intraarterial infusion of
acetylcholine, which were inhibited by L-
NMMA (Seddon et al. 2008) (Figure 1).
Flow-induced vasodilatation, which is
thought to be an eNOS-mediated re-
sponse and is inhibited by L-NMMA, was
also unaffected by SMTC (Seddon et al.
2009). Taken together, these results indi-
cate that reduction in basal blood flow
induced by SMTC results from selective
nNOS inhibition, a mechanism that is
independent of and is not required for
eNOS-mediated responses to acetylcho-
line or increased flow.
In further studies, Seddon et al.
(Seddon et al. 2009) also investigated
the potential role of local nNOS in the
human coronary circulation. The effects
of intracoronary infusion of SMTC were
studied in patients undergoing cardiac
catheterization who turned out to have
angiographically normal coronary arter-
ies. In these subjects, SMTC caused a
significant reduction in basal blood flow
as assessed by intracoronary Doppler
and angiography. However, SMTC had
no effect on the increases in flow elicited
by intracoronary substance P infusion,
which in contrast was inhibited by L-
NMMA (Seddon et al. 2009) (Figure 2).
These data indicate that the effects of
SMTC on basal flow extend to the
coronary circulation.
Previous studies with the use of L-
NMMA have suggested that local NO is at
least partly involved in mediating the
peripheral and coronary vasodilator
responses to mental stress, but the NOS
isoform that is responsible has not been
identified. With the use of a standardized
mental stress protocol (the Stroop test),
Seddon et al. (Seddon et al. 2008) found
that the forearm vasodilator response
was significantly attenuated by local
forearm infusion of either SMTC or L-
NMMA but not by a vasoconstrictor
(norepinephrine) that reduced basal
blood flow to a similar extent as the
NOS inhibitors. These results strongly
suggest a role for local nNOS-derived NO
in regulation of mental stress-induced
vasodilatation.
Kellogg et al. (2008) have recently
provided further evidence for a function-
al association between axonal activity
and nNOS-dependent regulation of vas-
cular tone. In a series of studies in
healthy volunteers, intradermal adminis-
tration of the highly specific nNOS
inhibitor 7-nitroindazole significantly at-
tenuated increases in cutaneous blood
flow in response to whole body heat, a
process which involves centrally mediat-
ed axonal reflexes, but had no influence
on blood flow changes in response to
local application of heat, which, in
contrast, involves locally mediated
reflexes (Kellogg et al. 2008).
Taken together, the above data indi-
cate that nNOS and eNOS have distinct
Figure 1. Effects of nNOS in the human forearm. Intraarterial infusion of the nNOS-specific
inhibitor STMC into the brachial artery resulted in a dose dependent reduction in forearm
blood flow (panel A). Maximal reduction in forearm blood flow in response to SMTC was
abolished in the presence of excess L-arginine but not D-arginine (panel B). Intraarterial
infusion of the eNOS-agonist acetylcholine (ACh) resulted in a dose-dependent increase in
forearm blood flow. This response was abolished in the presence of the nonselective NOS
inhibitor L-NMMA but was unaffected by SMTC. S-methyl-L-thiocitrulline had no effect on NO-
independent changes in blood flow in response to intraarterial sodium nitroprusside (SNP)
(panel C) (adapted from Seddon et al. 2008. Circulation 117:1991-1996).
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local roles in the physiologic regulation
of human coronary and peripheral mi-
crovascular tone in vivo and that these
isoforms may therefore subserve distinct
functions. Whereas eNOS-generated NO
facilitates dynamic alterations in blood
flow distribution (eg, in response to
altered shear stress) and has antiathero-
sclerotic effects at the level of the
endothelium, the tonic generation of
NO by nNOS may be important for the
regulation of basal vasomotor tone and
blood flow.
 Current perspectives and
future directions
The conventionally accepted notion that
tonic NO generation by endothelial
eNOS regulates basal microvascular
tone and blood flow is challenged by
emerging data indicating that basal mi-
crovascular tone may be primarily regu-
lated by local nNOS-derived NO (at least
in the human forearm and coronary
circulations), whereas eNOS may be
responsible for changes in tone occur-
ring in response to agonists or shear
stress (Figure 3). The potentially inde-
pendent regulation of basal flow versus
stimulated endothelium-mediated
increases in blood flow may account for
the poor correlation between these two
aspects of vascular function in clinical
studies, especially in disease settings
such as those that predispose to athero-
sclerosis where eNOS dysfunction may
be more prominent.
Many fundamental questions regard-
ing the local vascular influences of nNOS
remain unanswered. The precise site and
cellular source of nNOS that regulates
microvascular tone remains to be de-
fined. As outlined previously, evidence
from experimental studies suggests that
nNOS in the local vessel wall, perivascu-
lar nerves, and/or skeletal muscle could
be involved (Bauser-Heaton and Bohlen
2007, Hatanaka et al. 2006, Thomas et al.
1998). However, it is not yet known
which of these cellular sources is respon-
sible for the effects of nNOS on basal
microvascular tone in the human fore-
arm and coronary circulation. Further-
more, different sources of nNOS may be
involved in different beds or in different
local vascular responses (such as regula-
tion of basal tone, mental stress-induced
increases in flow, or changes in blood
flow during exercise).
The functional association between
vascular nNOS and eNOS with respect to
the regulation of tone and how this may
be altered in disease settings also
requires further study. Previous studies
in animal models have suggested that
there may be an inverse functional
association between the two NOS iso-
forms within the vascular wall, with an
up-regulation of nNOS when eNOS
Figure 2. Effects of nNOS in the human coronary circulation. IntracoronaryDoppler ultrasound
traces demonstrating average peak velocity (APV) values at baseline and after infusion of the
endothelial agonist substance P. Volumetric coronary blood flow can be obtained from the
product of APV values and the cross-sectional area of the coronary vessel (calculated from
measuring the diameter of the epicardial vesselwith the use of quantitative coronary angiography
[QCA]) at the time of APV recording (panel A). Doppler/QCA was used to derive changes in
coronary blood flow in response to the nNOS-selective inhibitor SMTC and the nonselective NOS
inhibitor L-NMMA during cardiac catheterization in patients who turned out to have
unobstructed/smooth coronary vessels. As in the forearm, intracoronary infusion of the SMTC
reduced coronary blood flow. This response was abolished in the presence of excess L-arginine
but not D-arginine (panel B). Intracoronary infusion of the eNOS-agonist substance P increased
coronary blood flow. This responsewas abolished in the presence of L-NMMAbut was unaffected
by SMTC (panel C) (adapted from Seddon et al. 2009. Circulation 119:2656-2662).
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expression is reduced (Boulanger et al.
1998). How this may impact on the
proposed distinct functions of eNOS
and nNOS remains to be assessed. An-
other important issue is the potential
impact of risk factors that lead to a
reduction in NO bioavailability on the
vascular actions of nNOS. It is well
established that eNOS-mediated actions
are impaired in the presence of hyper-
cholesterolemia, diabetes, obesity, and
systemic inflammation, and this is due at
least in part to dysfunctional NOS activ-
ity secondary to oxidation of the critical
cofactor tetrahydrobiopterin and/or di-
rect NO scavenging by reactive oxygen
species (Landmesser et al. 2004). What
impact these conditions might have on
nNOS-dependent regulation of vascular
tone requires investigation. In this re-
gard, it is intriguing that data from
cardiac muscle suggest that dysfunction-
al nNOS signaling may itself result in
increased reactive oxygen species gener-
ation (Eu et al. 2003, Kinugawa et al.
2005, Zhang et al. 2009).
Another important area that merits
further study is the potential role of
nNOS in the regulation of arterial blood
pressure. Although microvascular tone
would be expected to have a relatively
limited impact on blood pressure, the
fact that nNOS is also expressed in the
central nervous system and the kidneys
raises the possibility that its combined
actions in these three systems may have
significant effects on blood pressure
regulation. The availability of a selective
nNOS inhibitor validated for in vivo
human use now paves the way for further
direct investigation of some of these
questions thereby to increase under-
standing of the roles of nNOS in human
health and disease.
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Ras-Association Domain Family
Member 1A (RASSF1A)—Where the
Heart and Cancer Meet
Delvac Oceandy⁎, Elizabeth J. Cartwright, and Ludwig Neyses
The close relationship between signaling pathways regulating tumor
growth and cardiac hypertrophy has attracted considerable interest.
Although the involvement of proto-oncogenes in positively modulating
myocardial hypertrophy has long been recognized, little is known about
factorsthatcounterregulatethem.Inthisarticle,wereviewthenovel tumor
suppressor Ras-association domain family protein isoform 1A (RASS-
F1A), which strongly inhibits the prohypertrophic Ras-Raf1-ERK1/2
pathway in the heart. RASSF1A interacts with a number of important
signaling molecules regulating cell growth, survival, and apoptosis;
therefore, it serves as a key adaptor molecule that integrates the upstream
stimuli and transduces them to the selective downstream effectors.
(Trends CardiovascMed 2009;19:262–267)n 2009, Elsevier Inc.
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